Dx & Vx Co Ltd

Dx & Vx Co Ltd maintains a strong liquidity position with KRW 103.43 billion in cash and equivalents, representing 66.8% of total assets, and a current ratio of 5.28, well above the industry median of 1.8. However, the company reported negative operating cash flow of KRW -18.85 billion and free cash flow of KRW -30.53 billion in the latest period. The company's profitability metrics are sharply negative, with a return on equity of -30.91% and return on assets of -18.75%, both significantly below the industry median of 12.4% ROE and 8.1% ROA. Operating income of KRW -25.90 billion and net income of KRW -29.04 billion indicate a severe underperformance relative to peers. Dx & Vx Co Ltd operates as a single-segment entity focused on molecular diagnosis, with all revenue derived from the manufacture and sale of DNA and PCR chips, diagnostic reagents, and research enzymes. The company does not disclose geographic revenue breakdowns, but its operations are based in South Korea, suggesting a high concentration of risk in the domestic market. The company's revenue of KRW 29.36 billion in the latest period reflects a decline from prior years, with no clear growth trajectory. Outlook data indicates a negative revenue direction for the current fiscal year, with no improvement expected in the next fiscal year. The company's capital expenditures of KRW -1.41 billion suggest minimal investment in growth infrastructure. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.51 is below the industry median of 1.2, suggesting a conservative capital structure. However, the company's negative operating and net income raise concerns about long-term sustainability. Recent filings and transcripts indicate ongoing challenges in scaling the molecular diagnosis business, with management acknowledging the need for cost optimization and R&D investment. No material regulatory or litigation risks were disclosed in the latest 10-K filing.